Patents by Inventor Anthony James Taylor
Anthony James Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6306368Abstract: Aerosol formulations comprising: (A) A medicament in particulate form and having a surface coating of a surfactant; (B) A hydrogen-containing fluorocarbon or chlorofluorocarbon propellant; and (C) A cosolvent having higher polarity than the propellant which cosolvent is present in an amount of up to 5% w/w based upon propellant; and methods for their preparation.Type: GrantFiled: November 24, 1998Date of Patent: October 23, 2001Assignee: Glaxo Group LimitedInventors: Anthony James Taylor, Patricia Kwong Phieu Burnell
-
Patent number: 6303103Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: June 14, 2000Date of Patent: October 16, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6251368Abstract: A pharmaceutical aerosol formulation which comprises particulate medicament selected from the group consisting of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant is disclosed. Also disclosed is a method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the, pharmaceutical aerosol formulation which may be contained in a canister.Type: GrantFiled: June 17, 1997Date of Patent: June 26, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
Patent number: 6238647Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: November 2, 1999Date of Patent: May 29, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt -
Patent number: 6221339Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: GrantFiled: May 10, 1999Date of Patent: April 24, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6200549Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: March 9, 1999Date of Patent: March 13, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6013245Abstract: The present invention relates to a pharmaceutical aerosol formulation which comprises particulate anhydrous beclomethasone dipropionate together with 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant, which formulation is free of surfactant. The formulation may also contain salbutamol and includes a canister suitable for delivery and a method of treating respiratory disorders administering the formulation by inhilation.Type: GrantFiled: August 24, 1998Date of Patent: January 11, 2000Assignee: Glaxo Group LimitedInventors: Anthony James Taylor, Philip John Neale
-
Patent number: 5922306Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: April 15, 1998Date of Patent: July 13, 1999Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5919435Abstract: The present application relates to aerosol formulations comprising (1) a medicament in particulate form and having a surface coating of a surfactant, (2) a hydrogen-containing fluorocarbon or chlorofluorocarbon propellant, and (3) a co-solvent having higher polarity than the propellant, which cosolvent is present in an amount of up to 5% w/w based upon propellant. The invention also relates to methods for preparation of these aerosol formulations.Type: GrantFiled: May 12, 1995Date of Patent: July 6, 1999Assignee: Glaxo Group LimitedInventors: Anthony James Taylor, Patricia Kwong Phieu Burnell
-
Patent number: 5916540Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: GrantFiled: April 6, 1998Date of Patent: June 29, 1999Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5833950Abstract: This invention relates to novel aerosol formulations for administering drugs, in particular, for the administration of a beclomethasone ester, by inhalation. In particular, the invention provides novel aerosol formulations consisting essentially of (a) beclomethasone dipropionate in the form of a solvate with 1,1,1,2-tetrafluoroethane (CF.sub.3 CH.sub.2 F) and one or more fluorocarbon or hydrogen-containing chlorofluorocarbon propellants, or (b) anhydrous beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant.Type: GrantFiled: June 18, 1997Date of Patent: November 10, 1998Assignee: Glaxo Group LimitedInventors: Anthony James Taylor, Philip John Neale
-
Patent number: 5817293Abstract: This invention relates to a canister suitable for delivering a pharmaceutical aerosol formulation for inhalation therapy including a propellant which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation for inhalation therapy consisting essentially of a physiologically effective amount of particulate medicament, 1,1,1,2-tetrafluoroethane as propellant and up to 5% w/w based upon propellant of a polar co-solvent, which formulation is substantially free of surfactant.Type: GrantFiled: May 30, 1995Date of Patent: October 6, 1998Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5785952Abstract: The present application is directed to aerosol formulations comprising (1) a medicament which is selected from the group consisting of salmeterol, fluticasone esters, 4-amino-3,5-dichloro-.alpha.-???6-?2-(2-pyridinyl)ethoxy!hexyl!amino!methy l!benzenemethanol and physiologically acceptable salts and solvates thereof in particulate form and having a surface coating of a surfactant, and (2) a hydrogen-containing fluorocarbon or chlorofluorocarbon propellant. The invention also describes methods for preparation of these aerosol formulations.Type: GrantFiled: May 12, 1995Date of Patent: July 28, 1998Assignee: Glaxo Group LimitedInventors: Anthony James Taylor, Patricia Kwon Phieu Burnell
-
Patent number: 5744123Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: June 5, 1995Date of Patent: April 28, 1998Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5736124Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: May 30, 1995Date of Patent: April 7, 1998Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5695744Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises: (a) beclomethasone dipropionate monohydrate, the particle size of substantially all the monohydrate being less than 20 microns; (b) at least 0.015% by weight of the formulation of water in addition to the water of crystallization associated with the monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: July 12, 1994Date of Patent: December 9, 1997Assignee: Glaxo Group LimitedInventors: Philip John Neale, Anthony James Taylor
-
Patent number: 5688782Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises: (a) beclomethasone dipropionate monohydrate, the particle size of substantially all the monohydrate being less than 20 microns; (b) at least 0.015% by weight of the formulation of water in addition to the water of crystallization associated with the monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: June 2, 1995Date of Patent: November 18, 1997Assignee: Glaxo Group LimitedInventors: Philip John Neale, Anthony James Taylor
-
Patent number: 5683676Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salmeterol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: May 19, 1995Date of Patent: November 4, 1997Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5676929Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: May 19, 1995Date of Patent: October 14, 1997Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5674472Abstract: The present invention relates to canisters suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based on the weight of the medicament, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns. A further particulate medicament may also be present in the pharmaceutical aerosol formulation.Type: GrantFiled: May 19, 1995Date of Patent: October 7, 1997Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt